King's College Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

  NCT07672769· Phase 2· Faron Pharmaceuticals Ltd· Source

• Not yet recruiting

  Tenofovir Exposures in Advanced Kidney Disease Study

  NCT07812571· King's College Hospital NHS Trust· Source

• Not yet recruiting

  Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases

  NCT07791212· King's College London· Source

• Recruiting

  Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

  NCT07654283· Phase 2· AusperBio Therapeutics Inc.· Source

• Recruiting

  A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

  NCT07298421· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  Optimizing the Use of Aspirin for the Prevention of Preeclampsia

  NCT07665853· Phase 3· Hospital Universitari Vall d'Hebron Research Institute· Source

• Recruiting

  Heart Failure Carer Support Programme: Implementation Testing in the UK.

  NCT07373041· Queen's University, Belfast· Source

• Recruiting

  A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

  NCT07470879· Phase 2· Pfizer· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Takeda· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  NCT07226843· Phase 1· Eli Lilly and Company· Source

• Recruiting

  The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures

  NCT07027306· AO Foundation, AO Spine· Source

• Recruiting

  Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

  NCT07219459· Phase 2· CatalYm GmbH· Source

• Recruiting

  The International Spinal Cord Injury Blood Biomarker Longitudinal Evaluation (I-SCRIBBLE) Study

  NCT06839300· AO Foundation, AO Spine· Source

• Recruiting

  Can Tiny Bubbles Offer an Alternative to Catheters for Assessing Pressures Inside the Heart? Investigating Ultrasound Contrast Agents as Pressure Sensors Against Gold Standard Catheter Pressures in Cardiac Catheterisation Patients.

  NCT07416279· King's College London· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Prilenia· Source

• Recruiting

  A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B

  NCT07200193· Phase 1/2· nChroma Bio· Source

• Active, not recruiting

  Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

  NCT07161037· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

  NCT07087054· Phase 3· Crinetics Pharmaceuticals Inc.· Source

• Recruiting

  A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

  NCT06243731· Takeda· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT06979336· Phase 2· Genentech, Inc.· Source

• Recruiting

  HOPE Against Cancer Recurrence in HCC

  NCT06717919· Phase 4· Philipp Dutkowski· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

• Active, not recruiting

  A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

  NCT07015983· Phase 2· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Recruiting

  Deep Brain Stimulation to Understand and Treat Addiction

  NCT07341230· University of Cambridge· Source

• Recruiting

  A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979362· Phase 2· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· AbbVie· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

  NCT06962839· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

  NCT06782373· Phase 2· Swedish Orphan Biovitrum· Source

• Recruiting

  Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis

  NCT06940531· Alexander Horsley· Source

• Recruiting

  Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

  NCT06662162· i-Lumen Scientific AUS PTY LTD· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

• Recruiting

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

  NCT06671496· Phase 3· Takeda· Source

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease

  NCT06347536· Phase 3· Guy's and St Thomas' NHS Foundation Trust· Source

• Recruiting

  A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

  NCT06609226· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

  NCT06747572· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

  NCT06543914· AbbVie· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

  NCT06823713· Phase 1/2· Resolution Therapeutics Limited· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  NCT06625060· Phase 2· Ipsen· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

  NCT06193889· Phase 2/3· Kyverna Therapeutics· Source

Showing 50 of 117.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure6 recruiting
• Myelodysplastic syndromes5 recruiting
• Sickle cell disease5 recruiting
• Childhood cancers4 recruiting
• Fatty liver disease (MASLD/MASH)4 recruiting
• Multiple myeloma4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Acute myeloid leukaemia3 recruiting
• Chronic kidney disease3 recruiting
• Hepatitis B3 recruiting
• Liver and biliary tract cancer3 recruiting
• Liver cirrhosis3 recruiting
• Obesity3 recruiting
• Ulcerative colitis3 recruiting
• Bronchiectasis2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Coronary artery disease2 recruiting
• Cytomegalovirus infection2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Hodgkin lymphoma2 recruiting
• IgA nephropathy2 recruiting
• Osteoporosis2 recruiting
• ALS (motor neurone disease)1 recruiting
• Aortic stenosis1 recruiting
• Chronic myeloid leukaemia1 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Cystic fibrosis1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Diabetic eye disease1 recruiting
• Dystonia1 recruiting
• Epilepsy1 recruiting
• Essential tremor1 recruiting
• Follicular lymphoma1 recruiting
• High blood pressure1 recruiting
• HIV1 recruiting
• Macular degeneration1 recruiting
• Myasthenia gravis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Osteoarthritis1 recruiting
• Parkinson disease1 recruiting
• Polycystic kidney disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Schizophrenia1 recruiting
• Spinal cord injury1 recruiting
• Stroke1 recruiting
• Thalassaemia1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

  NCT06797869· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

  NCT06465186· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Ipsen· Source

• Recruiting

  A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

  NCT06321302· Phase 2· Boehringer Ingelheim· Source

• Completed

  Carry Life@ UF System Clinical Study

  NCT05874804· Triomed AB· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

  NCT05436639· Phase 2· Sparrow Pharmaceuticals· Source

• Completed

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT05442567· Phase 3· Takeda· Source

• Completed

  A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

  NCT05695950· Phase 2· Lakefront Biotherapeutics NV· Source

• Completed

  Phase Ib/IIa Trial With AC01 in Patients With HFrEF

  NCT05642507· Phase 1/2· AnaCardio AB· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Completed

  A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

  NCT05353985· Phase 2· Takeda· Source

• Completed

  Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

  NCT05232071· Phase 2· Inventiva Pharma· Source

• Completed

  A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

  NCT05249426· Phase 1· Boehringer Ingelheim· Source

• Completed

  Safe Management of People With Type 1 Diabetes and EAting Disorders studY

  NCT05140564· King's College London· Source

• Completed

  Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years

  NCT05126901· Phase 3· Shield Therapeutics· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Psilocybin in Depression Resistant to Standard Treatments

  NCT04959253· Phase 2· King's College London· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Boehringer Ingelheim· Source

• Completed

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Vifor (International) Inc.· Source

• Completed

  OpiCapone Effect on Motor Fluctuations and pAiN

  NCT04986982· Phase 4· Bial - Portela C S.A.· Source

• Terminated

  REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

  NCT04409080· Phase 1· Regeneron Pharmaceuticals· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

  NCT04166773· Phase 2· Eli Lilly and Company· Source

• Completed

  Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

  NCT04173533· Phase 3· University of Birmingham· Source

• Completed

  Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant

  NCT03131934· Early phase 1· University College, London· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

  NCT03573882· Phase 3· Pfizer· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· LivaNova· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· University College Dublin· Source

• Terminated

  Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

  NCT02629692· Phase 1/2· Sun Pharma Advanced Research Company Limited· Source

• Completed

  MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease

  NCT04116242· University Hospital, Basel, Switzerland· Source

• Recruiting

  Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

  NCT02071134· Boston Scientific Corporation· Source

• Completed

  Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers

  NCT01597219· Phase 2· University College, London· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Fatty liver disease (MASLD/MASH)35 works · 8 trials
• Lupus (SLE)27 works · 1 trial
• Psoriasis26 works · 1 trial
• Rheumatoid arthritis24 works · 0 trials
• Migraine16 works · 2 trials
• Hepatitis B16 works · 3 trials
• ALS (motor neurone disease)16 works · 2 trials
• Sickle cell disease15 works · 7 trials
• Ankylosing spondylitis13 works · 0 trials
• Dystonia9 works · 1 trial
• Myelodysplastic syndromes9 works · 9 trials
• Psoriatic arthritis8 works · 1 trial
• Primary biliary cholangitis7 works · 3 trials
• Dermatomyositis and polymyositis (myositis)6 works · 1 trial
• Gastroparesis6 works · 0 trials
• Giant cell arteritis4 works · 0 trials
• Aplastic anaemia4 works · 1 trial